Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017040620) ANTAGONISTIC PDL1 APTAMERS AND THEIR APPLICATIONS IN CANCER THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/040620 International Application No.: PCT/US2016/049643
Publication Date: 09.03.2017 International Filing Date: 31.08.2016
IPC:
C12N 15/115 (2010.01) ,A61K 31/711 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
115
Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
711
Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Applicants:
ACADEMIA SINICA; 128 Academia Road Section 2, Nankang Taipei, 115, TW
NATIONAL TAIWAN UNIVERSITY; No. 1, Sec. 4, Roosevelt Road Taipei, 10617, TW
Inventors:
YANG, Pan-Chyr; TW
LAI, Wei-Yun; TW
HUANG, Bo-Tsang; TW
Agent:
CHEN, Yahua; US
Priority Data:
62/212,77201.09.2015US
Title (EN) ANTAGONISTIC PDL1 APTAMERS AND THEIR APPLICATIONS IN CANCER THERAPY
(FR) APTAMÈRES PDL1 ANTAGONISTES ET LEURS APPLICATIONS DANS LA THÉRAPIE DU CANCER
Abstract:
(EN) Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.
(FR) L'invention concerne des aptamères qui se lient à et ont un effet antagoniste sur PDL1 et leurs utilisations dans l'amélioration de l'activité immunitaire (par exemple en favorisant la prolifération des lymphocytes T), le traitement du cancer, et/ou de maladies infectieuses telles que des infections causées par un entérovirus, un VHB, ou une infection par le VHC.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)